Appl. No. 09/485,571 Amdt. dated September 18, 2006 Reply to office action of March 17, 2006

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

Claims 1 - 17 (cancelled)

Claim 18: (currently amended): An isolated linear peptide obtained from an antibiotic peptide consisting of the sequence: Arg-Arg-Leu-Ser-Tyr-Ser-Arg-Arg-Arg-Phe (SEQ ID NO: 23), wherein said isolated peptide is devoid of a disulphide bond.

Claim 19: (previously presented): The isolated linear peptide of claim 18, wherein the antibiotic peptide is a β -stranded antibiotic peptide.

Claim 20: (currently amended): A method for vectoring a chemical molecule to a target in vitro using a conjugate of said chemical molecule and a linear peptide having consisting of a sequence of SEQ. ID NO:23, wherein said linear peptide is devoid of disulphide bonds, said disulphide bonds being removed, replaced by another amino acid or wherein one or more cysteines in said peptide is blocked at the SH group level, said method comprising the steps of:

- (a) coupling said conjugate of said chemical molecule to said linear peptide to form a conjugate; and
- (b) conveying said conjugate of said chemical molecule coupled with said linear peptide to a target for vectoring, said target being selected <u>is</u> from the group consisting of a

Appl. No. 09/485,571 Amdt. dated September 18, 2006 Reply to office action of March 17, 2006

particular cell compartment, or a particular cell type, and a particular organ.

Claims 21 - 23. (cancelled)

Claim 24: (currently amended): A method of vectoring a chemical molecule to a target in vitro using a conjugate of said chemical molecule and a linear peptide according to claim 18, the method comprising the steps of:

- (a) coupling said conjugate of said chemical molecule to said linear peptide to form said conjugate; and
- (b) conveying said conjugate of said chemical molecule coupled with said linear peptide to a target for vectoring, said target being selected is from the group consisting of a particular cell compartment, or a particular cell type and a particular organ.

Claims 25 - 28. (cancelled)

Claim 29: (currently amended): A compound of formula (IV):

$$(Y)_n - (A) - Z_m$$

wherein:

A is an the amino acid sequence of SEQ ID NO: 23;

Z is biotin, doxorubicin or a chemical molecule of an antitumor or antibacterial agent;

Appl. No. 09/485,571 Amdt. dated September 18, 2006 Reply to office action of March 17, 2006

Y represents a signal agent selected from the group consisting of oligopeptides, proteins, antibodies and chemical ligands, said signal agent having an affinity towards a particular cell type, or a cell compartment or a specific tissue or organ, or the ability to recognize a specific determinant present on a particular cell type, or a cell compartment or a specific tissue or organ;

N is 0; and

m is 1.

Claim 30: (previously presented): The compound according to claim 29, wherein at least one of said biotin, said doxorubicin or said chemical molecule (Z) is attached by a covalent bond to either the N-terminal or C-terminal ends of linear peptide (A).

Claims 31 - 32. (cancelled)

Claim 33: (Cancelled)

Claim 34: (Cancelled)

Claims 35 - 36. (cancelled)

Claim 37: (Cancelled)

Claim 38. (Cancelled)